Eli Lilly and Company
$ 1154.97
-4.55%
30 Jul - close price
- Market Cap 1,057,489,355,000 USD
- Current Price $ 1154.97
- High / Low $ 1186.65 / 1153.14
- Stock P/E 43.29
- Book Value 34.92
- EPS 27.95
- Next Earning Report 2026-08-05
- Dividend Per Share $6.23
- Dividend Yield 0.51 %
- Next Dividend Date 2026-09-10
- ROA 0.21 %
- ROE 1.07 %
- 52 Week High 1249.45
- 52 Week Low 619.40
About
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Analyst Target Price
$1276.96
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-02-04 | 2025-10-30 | 2025-08-07 | 2025-05-01 | 2025-02-06 | 2024-10-30 | 2024-08-08 | 2024-04-30 | 2024-02-06 | 2023-11-02 | 2023-08-08 |
| Reported EPS | 8.55 | 7.54 | 7.02 | 6.31 | 3.34 | 5.32 | 1.18 | 3.92 | 2.58 | 2.49 | 0.1 | 2.11 |
| Estimated EPS | 6.79 | 7.17 | 5.89 | 5.61 | 3.46 | 5.0668 | 1.47 | 2.77 | 2.49 | 2.37 | -0.12 | 1.99 |
| Surprise | 1.76 | 0.37 | 1.13 | 0.7 | -0.12 | 0.2532 | -0.29 | 1.15 | 0.09 | 0.12 | 0.22 | 0.12 |
| Surprise Percentage | 25.9205% | 5.1604% | 19.1851% | 12.4777% | -3.4682% | 4.9972% | -19.7279% | 41.5162% | 3.6145% | 5.0633% | 183.3333% | 6.0302% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 6.71 |
| Currency | USD |
Previous Dividend Records
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-09-10 | 2026-06-10 | 2026-03-10 | 2025-12-10 | 2025-09-10 | 2025-06-10 | 2025-03-10 | 2024-12-10 | 2024-09-10 | 2024-06-10 |
| Amount | $1.73 | $1.73 | $1.73 | $1.5 | $1.5 | $1.5 | $1.5 | $1.3 | $1.3 | $1.3 |
Next Dividend Records
| Dividend per share (year): | $6.23 |
| Dividend Yield | 0.51% |
| Next Dividend Date | 2026-09-10 |
| Ex-Dividend Date | 2026-08-14 |
Recent News: LLY
2026-07-30 22:35:53
The biopharmaceutical industry has seen active mergers and acquisitions, highlighted by Vertex Pharmaceuticals' $10 billion acquisition of Crinetics Pharmaceuticals. This article suggests that Viking Therapeutics, with its promising weight loss drug pipeline including VK2735 currently in Phase 3 trials, could be the next major takeover target, especially given the rapidly expanding anti-obesity market projected to reach $190 billion by 2035. While Viking Therapeutics presents significant potential, its stock is also considered risky due to the binary nature of upcoming Phase 3 data readouts for its leading program.
2026-07-30 19:21:58
Johnson & Johnson is entering the next-generation cell therapy space for autoimmune diseases by partnering with Sail Biomedicines. The deal involves an initial payment of $785 million, including an equity investment, and provides J&J with an exclusive option to acquire Sail for an additional $2.85 billion. This partnership aims to leverage Sail's in vivo cell therapy platform to develop treatments that achieve immune system reset, strengthening J&J's immunology pipeline.
2026-07-30 15:08:09
Eli Lilly and Co (LLY) stock experienced a 4.09% decline on July 30, driven by profit-taking, increasing competitive pressure in the weight-loss market from rival GLP-1 candidates, and regulatory concerns over Medicare price negotiations impacting large-cap pharmaceutical stocks. Technical factors like broken moving averages and month-end portfolio rebalancing also contributed to the intraday volatility. The decline reflects a valuation reset amid market maturation and competitive testing, despite a robust pipeline.
2026-07-30 14:12:14
Bristol Myers Squibb has once again delayed the phase 3 data readout for its Alzheimer's disease psychosis drug, Cobenfy, moving the expected arrival of data to early 2027 due to slower patient enrollment and relapse event accrual. Despite this setback and a muted launch for Cobenfy in schizophrenia, BMS reported a strong quarterly beat with total revenue of nearly $13 billion, driven by robust sales of Eliquis and Revlimid, leading to a significant raise in its full-year revenue outlook. Another key program, Librexia-AF, also saw its readout delayed to 2027.
2026-07-30 12:58:00
Eli Lilly and contract manufacturer Resilience are investing $750 million to expand pharmaceutical manufacturing capacity in the U.S. and bolster the domestic medicine supply chain. This investment will create 400 new jobs in Cincinnati, Ohio, and include the production of Lilly's KwikPen injectable device. The move aligns with a broader trend of drugmakers increasing U.S. manufacturing amid potential tariffs and responds to rising demand for Lilly's medicines.
2026-07-30 12:38:10
Jim Cramer expressed his positive view on Eli Lilly (NYSE: LLY), calling it a "good company" he intends to hold for years due to its strong business and drugs. However, he stated he doesn't "really care for" Rigetti Computing, Inc (NASDAQ: RGTI), despite its expanded collaboration with Hewlett Packard Enterprise Co. (NYSE: HPE). Cramer also mentioned Astera Labs, Inc. (NASDAQ: ALAB) as a buy and was unfamiliar with MakeMyTrip Limited (NASDAQ: MMYT).
